97337 ⎘
Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
METHOD FOR THE PRODUCTION OF BI-FUNCTIONAL CELLS TO TREAT NEOPLASIA
#902T-cells comprising two different chimeric antigen receptors and uses thereof
#903Compositions and methods for transient gene therapy with enhanced stability
#904Modified T lymphocytes comprising a CD52 antibody-inducible caspase and methods of apoptosis
#905CHIMERIC ANTIGEN RECEPTORS
#906Chimeric immunogenic polypeptides
#907Coordinating Gene Expression Using RNA Destabilizing Elements
#908IMPROVING THE EFFICACY AND SAFETY OF ADOPTIVE CELLULAR THERAPIES
#909ANTIBODIES SPECIFIC TO FOLATE RECEPTOR ALPHA
#910MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF
#911PD1-4-1BBL variant fusion protein and methods of use thereof
#912IMMUNE-MEDIATED CORONAVIRUS TREATMENTS
#913CAR T CELL THERAPY TO TARGET T CELL SPECIFIC CANCERS
#914Anti-PSMA antibodies and use thereof
#915BCMA-CAR-natural killer (NK) cells and methods related thereto
#916CD70 binding molecules and methods of use thereof
#917TRANSFORMING GROWTH FACTOR-BETA-RESPONSIVE POLYPEPTIDES AND THEIR METHODS FOR USE
#918CRP capture/detection of gram positive bacteria
#919RECOMBINANT TRANSMEMBRANE DOMAIN-DEFICIENT STING AS BIOMIMETIC PROTEIN CARRIER FOR CGAMP ENHANCED CANCER IMMUNOTHERAPY
#920NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS
#921Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers
#922Trispecific T cell engagers
#923Antibody binding to chondroitin sulfate proteoglycan 5
#924Anti-mesothelin chimeric antigen receptor (CAR) constructs and uses thereof
#925Cell surface coupling of nanoparticles
#926Tissue targeted immunotolerance with a CD39 effector
#927Cell-targeting molecules comprising de-immunized, Shiga toxin a subunit effectors and CD8+ t-cell epitopes
#928CHIMERIC ANTIGEN RECEPTORS TARGETING CD37 AND CD19
#929Notch receptors with hinge domain
#930COMPOSITIONS AND METHODS FOR ENHANCING THE UBIQUITIN PROTEASOME SYSTEM
#931Methods and compositions for treating cancer
#932Antibody immune cell inhibitor fusion proteins
#933CHIMERIC ANTIGEN RECEPTORS BASED ON SINGLE-DOMAIN ANTIBODIES AND METHODS OF USE THEREOF
#934Restimulation of cryopreserved tumor infiltrating lymphocytes
#935ENHANCED CHIMERIC ANTIGEN RECEPTORS AND USE THEREOF
#936Compositions and Methods for Retrieving Tumor-related Antibodies and Antigens
#937Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS
#938LIGAND-BINDING MOLECULE CONTAINING SINGLE DOMAIN ANTIBODY
#939Antibody/T-cell receptor chimeric constructs and uses thereof
#940De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
#941MHC class I epitope delivering polypeptides
#942REAGENTS AND METHODS FOR IDENTIFYING, ENRICHING, AND/OR EXPANDING ANTIGEN-SPECIFIC T CELLS
#943Restimulation of cryopreserved tumor infiltrating lymphocytes
#944Restimulation of cryopreserved tumor infiltrating lymphocytes
#945Materials and methods for engineering cells and uses thereof in immuno-oncology
#946CHIMERIC ANTIGEN RECEPTOR DENDRITIC CELL (CAR-DC) FOR TREATMENT OF CANCER
#947Methods and compositions for treating cancer
#948Methods for improving the efficacy and expansion of immune cells
#949EphA3 directed CAR-T cells for treatment of tumors
#950Interleukin-2 fusion proteins and uses thereof
#951Administration of Engineered T Cells for Treatment of Cancers in the Central Nervous System
#952Erythrocyte-binding therapeutics
#953TARGETING OF HUMAN INTERFERON ANTAGONISTS
#954Materials and methods for engineering cells and uses thereof in immuno-oncology
#955Materials and methods for engineering cells and uses thereof in immuno-oncology
#956NATURAL KILLER CELLS ENGINEERED TO EXPRESS CHIMERIC ANTIGEN RECEPTORS WITH IMMUNE CHECKPOINT BLOCKADE
#957Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
#958Core domain of annexins and uses thereof in antigen delivery and vaccination
#959Personalized immunotherapy against several neuronal and brain tumors
#960Method of treating a tumor expressing carbonic anhydrase IX (G250) by administering a G250-specific chimeric antigen receptor
#961BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR AND USES THEREOF
#962Chimeric antigen receptor and application thereof
#963CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
#964MATERIALS AND METHODS FOR TREATING CANCER
#965CHIMERIC ANTIGEN RECEPTORS AND GENE EDITING OF CD2 FOR IMMUNOTHERAPY OF T-CELL MALIGNANCIES
#966CLDN 18.2-specific monoclonal antibodies and methods of use thereof
#967Anti-VEGF protein compositions and methods for producing the same
#968IMMUNORESPONSIVE CELLS EXPRESSING DOMINANT NEGATIVE FAS AND USES THEREOF
#969IL-13/IL-4 SUPERKINES: IMMUNE CELL TARGETING CONSTRUCTS AND METHODS OF USE THEREOF
#970IMPROVED THERAPEUTIC T CELL
#971GENETICALLY ENGINEERED CELL AND APPLICATION THEREOF
#972Transgenic macrophages, chimeric antigen receptors, and associated methods
#973Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
#974CAR-CD30 T cells for treatment of CD30+ tumors
#975Anti-B7-H6 antibody, fusion proteins, and methods of using the same
#976Compositions and methods for treating HIV/AIDS with immunotherapy
#977Anti-VEGF protein compositions and methods for producing the same
#978CYTOKINE FUSION POLYPEPTIDE AND CYTOKINE LIBRARY COMPRISING SAME
#979Cell-penetrating peptides and methods of use thereof
#980FC-EPSILON CAR (Very imp commercially - in clinical trial)
#981CHIMERIC ANTIGEN RECEPTOR AND METHODS OF USE THEREOF
#982QUALITY OF IMMUNOLOGICAL SYNAPSE PREDICTS EFFECTIVENESS OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS
#983Inducible Cell Receptors for Cell-Based Therapeutics
#984METHODS FOR INCREASING RED BLOOD CELL LEVELS AND TREATING SICKLE-CELL DISEASE
#985PEPTIDES HAVING SPECIFICITY FOR THE LUNGS
#986NK-92 Cells to Stimulate Anti-Cancer Vaccine
#987ADAPTER-BASED RETROVIRAL VECTOR SYSTEM FOR THE SELECTIVE TRANSDUCTION OF TARGET CELLS
#988Membrane-Receiver Complex Therapeutics
#989Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
#990METHODS AND MATERIALS FOR TREATING CANCER
#991BI-FUNCTIONAL ALLOSTERIC PROTEIN-DRUG MOLECULES FOR TARGETED THERAPY
#992Engineered Non-Human Derived Immune Cells for Universal Adoptive Antigen Cellular Immunotherapy
#993Genome editing of graft-derived T-cells for post-transplant immunotherapy
#994METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR?EXPRESSING CELLS
#995Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
#996Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy
#997Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy
#998Anti-VEGF protein compositions and methods for producing the same
#999LEUCINE ZIPPER-BASED COMPOSITIONS AND METHODS OF USE
#1000ENOLASE 1 (ENO1) COMPOSITIONS AND USES THEREOF
#1001Chimeric antigen receptors targeting BCMA and methods of use thereof
#1002Cytokine fusion proteins, and their pharmaceutical compositions and therapeutic applications
#1003FUSION PROTEINS COMPRISING A BINDING PROTEIN AND AN INTERLEUKIN-15 POLYPEPTIDE HAVING A REDUCED AFFINITY FOR IL15Ra AND THERAPEUTIC USES THEREOF
#1004EXOSOME PACKAGING AND TARGETED AUTOPHAGY
#1005Modified Cell Expressing Therapeutic Agent and Uses thereof
#1006CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY
#1007MONOCLONAL ANTIBODY TARGETING A UNIQUE SIALOGLYCOSYLATED CANCER-ASSOCIATED EPITOPE OF CD43
#1008Humanized BCMA antibody and BCMA-CAR-T cells
#1009ANTIBODY-MODIFIED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELL AND USES THEREOF
#1010Engineered microbe-targeting molecules and uses thereof
#1011NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NHL AND OTHER CANCERS
#1012Compositions and methods for CD20 immunotherapy
#1013Humanized DR4 antibody gene having apoptosis-inducing activity and dual-acting chimeric antigen receptor T cell or natural killer cell therapeutic agent using same
#1014METHODS TO AUGMENT OR ALTER SIGNAL TRANSDUCTION
#1015IL-15 and IL-15R\alpha sushi domain based immunocytokines
#1016ICAM-1 targeted fusion enzymes
#1017Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers
#1018METHODS FOR ADOPTIVE CELL THERAPY TARGETING ROR1
#1019Compositions and methods for gene editing
#1020Methods and compositions for reducing immunosuppression by tumor cells
#1021TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR
#1022Production of engineered T-cells by sleeping beauty transposon coupled with methotrexate selection
#1023CELL-TARGETING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES
#1024Oncolytic HSV vector
#1025TARGETING OF MULTIPLE ANTIGENS WITH MULTIPLEX CAR T CELLS IN SOLID AND LIQUID MALIGNANCIES
#1026PROSTATE-SPECIFIC MEMBRANE ANTIGEN CARS AND METHODS OF USE THEREOF
#1027COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
#1028Modified TCR and uses thereof
#1029COMBINATION THERAPY WITH TARGETED TGF-B INHIBITION FOR TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
#1030Recombinant protein targeting PD-1 and TGFß
#1031USE OF A PEPTIDE DERIVED FROM THE HUMAN PROTEIN NTIMP3 IN THE TREATMENT OF DIABETIC NEPHROPATHY
#1032Glycan-dependent immunotherapeutic molecules
#1033TREATMENT OF STAGE III NSCLC AND MITIGATION OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH THE TREATMENT
#1034METHODS AND COMPOSITIONS FOR TH9 CELL MEDIATED CANCER TREATMENT
#1035Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
#1036Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
#1037Materials and methods for engineering cells and uses thereof in immuno-oncology
#1038PLAP-CAR-effector cells
#1039CARTYRIN COMPOSITIONS AND METHODS FOR USE
#1040Constructs specifically recognizing glypican 3 and uses thereof
#1041Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
#1042Precision activation of HIV-specific CTLS to eliminate reactivated latent T cells
#1043Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
#1044METHODS FOR IMPROVING ADOPTIVE CELL THERAPY
#1045Engineered T cell receptors and immune therapy using the same
#1046Broadly neutralizing anti-HIV-1 antibodies that bind to an N-glycan epitope on the envelope
#1047Chimeric antibody/T-cell receptor constructs and uses thereof
#1048Enzyme-mediated depletion of adenosine and/or methylthioadenosine
#1049Fusion Proteins Containing CD47 Antibodies and Cytokines
#1050Combination therapy with targeted 4-1BB (CD137) agonists
#1051Therapeutic agents
#1052Targeted immunotolerance
#1053Methods and materials for treating cancer
#1054Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers
#1055Anti-abeta therapeutic vaccines
#1056REGULATABLE CHIMERIC ANTIGEN RECEPTOR
#1057BISPECIFIC ANTIBODY CAR CELL IMMUNOTHERAPY
#1058Materials and methods for engineering cells and uses thereof in immuno-oncology
#1059Erythrocyte-binding therapeutics
#1060Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
#1061COMPOSITIONS AND METHODS FOR CELLULAR IMMUNOTHERAPY
#1062CD19 variants
#1063COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
#1064Peptide hydrogels and use thereof
#1065Method for preparing CAR-T cell with TCM as main active component and use thereof
#1066Anti-fungal inhibitors
#1067Compositions and methods for immunooncology
#1068HLA-G AS A NOVEL TARGET FOR CAR T-CELL IMMUNOTHERAPY
#1069Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same
#1070ANTIGENIC PEPTIDES DERIVING FROM SECRETOGRANIN V AND USES THEREOF FOR THE DIAGNOSIS AND TREATMENT OF TYPE 1 DIABETES
#1071Vaccine molecules
#1072Lysosomal Targeting Peptides and Uses Thereof
#1073FUSION PROTEIN COMPRISING MULTIPLE HINGE SEQUENCES
#1074COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASE
#1075Oncolytic virus platform to treat cancers with myxoma virus
#1076Methods and compositions for treating cancer
#1077Enhanced immune cells using dual shRNA and composition including the same
#1078ENZYME-MEDIATED DEPLETION OF ADENOSINE AND/OR METHYLTHIOADENOSINE
#1079Modified NK-92 cells for treating cancer
#1080Antibodies to tumour antigens
#1081IMMUNE CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR
#1082Recombinant herpes simplex virus having expression cassette expressing fused protein of cancer cell-targeting domain and extracellular domain of HVEM and use thereof
#1083DIRECT IMMUNOHISTOCHEMISTRY AND IMMUNOCYTOCHEMISTRY METHODS
#1084CAR T CELL THERAPIES WITH ENHANCED EFFICACY
#1085Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
#1086METHOD FOR REGULATING ANTIGEN-SPECIFIC MHC EXPRESSION
#1087Nanobodies suitable for neuron regeneration therapy
#1088Targeted protein contrast agents, methods of making, and uses thereof
#1089Method for Delivering Drug to Muscle
#1090CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
#1091Methods And Compositions Comprising A Viral Vector For Expression Of A Transgene And An Effector
#1092Methods of treating T cell exhaustion by inhibiting or modulating T cell receptor signaling
#1093Antibodies to galectin-3 and methods of use thereof
#1094POLYPEPTIDES AND METHODS
#1095Compositions and methods for targeted cytokine delivery
#1096MODULATING T CELL FUNCTION AND RESPONSE
#1097MODIFIED PSEUDOMONAS EXOTOXIN A
#1098NKG2D CHIMERIC ANTIGEN RECEPTORS
#1099HUMAN PAPILLOMAVIRUS VACCINES AND USES OF THE SAME
#1100Peptides and combination of peptides for use in immunotherapy against NHL and other cancers
#1101Factor IX polypeptides and methods of use thereof
#1102CAR-Treg-based therapies for treating neurodegenerative diseases
#1103Cellular immunotherapy compositions and uses thereof
#1104Multifunctional immune cell therapies
#1105CELL-TARGETING MOLECULES COMPRISING PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CARBOXY-TERMINAL MOIETIES
#1106METHODS OF PRODUCING CELLS EXPRESSING A RECOMBINANT RECEPTOR AND RELATED COMPOSITIONS
#1107CELLULAR SIGNALING DOMAIN ENGINEERING IN CHIMERIC ANTIGEN RECEPTOR-MODIFIED REGULATORY T CELLS
#1108Fusion Molecules Targeting Immune Regulatory Cells and Uses Thereof
#1109Hepatitis B vaccines and uses of the same
#1110CHIMERIC ANTIGEN RECEPTORS FOR TREATMENT OF NEURODEGENERATIVE DISEASES AND DISORDERS
#1111SOLUBLE FGFR3 DECOYS FOR TREATING SKELETAL GROWTH DISORDERS
#1112FACTOR IX POLYPEPTIDES AND METHODS OF USE THEREOF
#1113CAR-T cells targeting IL-1RAP and their use
#1114Treatment of cancer using a CD123 chimeric antigen receptor
#1115Transgene genetic tags and methods of use
#1116Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
#1117Targeted gene integration of CRS inhibitor genes for improved immune cells therapy
#1118Trophoblast glycoprotein (5T4, TPBG) specific chimeric antigen receptors for cancer immunotherapy
#1119ANTI CD30 CHIMERIC ANTIGEN RECEPTOR AND ITS USE
#1120A RECOMBINANT PROTEIN COMPRISING A DOUBLE STRANDED RNA BINDING DOMAIN
#1121Materials and methods for engineering cells and uses thereof in immuno-oncology
#1122Materials and methods for engineering cells and uses thereof in immuno-oncology
#1123Chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
#1124Articles and methods directed to personalized therapy of cancer
#1125Methods and compositions for therapeutic protein delivery
#1126Dimeric antigen receptors
#1127Humanized BCMA antibody and BCMA-CAR-T cells
#1128CAR-T CELLS AND AUTOIMMUNE DISEASES
#1129Anti-annexin A2 monoclonal antibodies
#1130CO-STIMULATORY DOMAINS FOR USE IN GENETICALLY-MODIFIED CELLS
#1131Targeted protein contrast agents, methods of making, and uses thereof
#1132Compositions and methods for targeting CD99-expressing cancers
#1133Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers
#1134COMPOSITIONS TO DISRUPT PROTEIN KINASE A ANCHORING AND USES THEREOF
#1135Use of chimeric antigen receptor modified cells to treat cancer
#1136Antibody
#1137Antibody-Mediated Transduction Of Heat Shock Proteins Into Living Cells
#1138IMMUNOTHERAPEUTIC COMPOSITION FOR THE TREATMENT OF CANCER
#1139Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers
#1140Polynucleotides encoding rituximab-resistant chimeric antigen receptors
#1141METHODS AND COMPOSITIONS COMPRISING CART AND A SMAC MIMETIC
#1142ELIMINATION OF CD19-POSITIVE LYMPHOID MALIGNANCIES BY CD19-CAR EXPRESSING NK CELLS
#1143Targeting B cell activating factor receptor (BAFF-R) using ligand-based chimeric antigen receptor (CAR)-T cells
#1144Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors
#1145CELLULAR BASED THERAPIES TARGETING DISEASE-ASSOCIATED MOLECULAR MEDIATORS OF FIBROTIC, INFLAMMATORY AND AUTOIMMUNE CONDITIONS
#1146Compositions comprising an anti-metallothionein antibody and a pancreatic cell targeting moiety
#1147DOMINANT NEGATIVE LIGAND CHIMERIC ANTIGEN RECEPTOR SYSTEMS
#1148ARTICLES AND METHODS DIRECTED TO PERSONALIZED THERAPY OF CANCER
#1149Compositions and methods for TCR reprogramming using fusion proteins
#1150ANTIBODY-MEDIATED DELIVERY OF CAS9 TO MAMMALIAN CELLS
#1151Molecular Size of Elastin-Like Polypeptide Delivery System for Therapeutics Modulates Deposition in the Placenta
#1152Method of redirecting t cells to treat HIV infection
#1153Engineered polypeptides having enhanced duration of action
#1154Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors
#1155Antigen binding molecules specific for an anti-CD19 scFv
#1156ANTI-GLYCOPROTEIN IIb/IIIa ANTIBODIES
#1157CARS AND BISPECIFIC ANTIBODIES FOR TREATMENT OF MANTLE CELL LYMPHOMA
#1158Chimeric antigen receptors comprising a human transferrin epitope sequence
#1159XCR1 BINDING AGENTS AND USES THEREOF
#1160Regulatory T cell expressing a chimeric antigen receptor
#1161USE AND PRODUCTION OF ENGINEERED IMMUNE CELLS TO DISRUPT NFAT-AP1 PATHWAY TRANSCRIPTION FACTORS
#1162TISSUE FACTOR-TARGETING CAR-NK AND CAR-T CELL THERAPY
#1163Activation of APC in immunotherapy
#1164METHODS FOR ENHANCING AND MAINTAINING CAR-T CELL EFFICACY
#11654-1BB antibody and preparation method and use thereof
#1166EPHA3 and multi-valent targeting of tumors
#1167De novo design of potent and selective interleukin mimetics
#1168USES OF AMPHIPHILES IN IMMUNE CELL THERAPY AND COMPOSITIONS THEREFOR
#1169Compositions and methods for targeting CLEC12A-expressing cancers
#1170Prostate-specific membrane antigen cars and methods of use thereof
#1171Reducing immune inhibition induced by SIGLEC-15
#1172Antibody fusion protein and related compositions for targeting cancer
#1173De novo design of potent and selective interleukin mimetics
#1174CELL
#1175Therapeutic agents
#1176Materials and methods for engineering cells and uses thereof in immuno-oncology
#1177T cells surface-loaded with immunostimulatory fusion molecules and uses thereof
#1178Oncolytic virotherapy with helper-dependent adenoviral-based vectors expressing immunomodulatory molecules
#1179ENGINEERED CELLS FOR ADOPTIVE CELL THERAPY
#1180COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13R-alpha-2
#1181Anti-CD70 chimeric antigen receptors
#1182Split superantigens and their use for immunotherapy
#1183Compositions and methods for immunotherapy
#1184Enhanced chimeric antigen receptors and uses thereof
#1185Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity
#1186Serine protease molecules and therapies
#1187Chimeric antigen receptors targeted to PSCA
#1188Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
#1189GENETICALLY ENCODED FLUORESCENT-IRON FERRITIN NANOPARTICLE PROBES FOR DETECTING AN INTRACELLULAR TARGET BY FLUORESCENT AND ELECTRON MICROSCOPY
#1190COMPOSITIONS AND METHODS FOR TARGETED TUMOR IMMUNOTHERAPY
#1191Restimulation of cryopreserved tumor infiltrating lymphocytes
#1192Method for providing personalized cells with chimeric antigen receptors (CAR)
#1193Blood-Brain Barrier Shuttles Containing Antibodies Recognizing Alpha-Synuclein
#1194Peptides and combination of peptides for use in immunotherapy against NHL and other cancers
#1195PRODUCTION OF ANTIGEN-SPECIFIC T-CELLS
#1196Cell secreted minibodies and uses thereof
#1197Chimeric antigen receptors, compositions, and methods
#1198COMPOSITIONS AND METHODS FOR TREATING DISEASES
#1199Constitutively active chimeric cytokine receptors
#1200Killer cell capable of efficiently and stably expressing antibody, and uses thereof